Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

Exclusion Criteria

• •1. Pregnant or lactating women, as well as women planning pregnancy within one year.
• •2. Current use medications with major effects on appetite regulation or weight (including, but not limited to systemic glucocorticoids and antipsychotic medication)
• •3. Renal failure with estimated glomerular filtration rate less than 30 mL/min/1,73m2
• •4. Liver failure with either ASAT and/or ALAT 5 times upper reference limit, or ALP and/or GT more than 3 times upper reference limit, or clinical signs of liver decompensation
• •5. Active cancer
• •6. Previous medullary thyroid cancer
• •7. Previous pancreatitis
• •8. Active substance abuse (but previous drug abuse accepted)
• •9. Medical or psychological treatment within the specialized health care service for eating disorders within the last 6 months.
• •10. Ongoing severe psychiatric disease that makes them unable to follow the lifestyle treatment program
• •11. Any illness or prior treatment that in the opinion of the investigator would jeopardize the patient's participation in the study or impact integrity and/or quality of study data.
• •12. Previous bariatric surgery
• •13. Use of appetite suppressing drugs (e.g., GLP-1 analogues and/or naltrexone/bupropion) within the last 6 months
• •14. Participation in another clinical study involving an investigational medicinal product within 1 month prior to study inclusion